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Abstract
Background: The ability of mesenchymal stem cells (MSCs) to modulate immune responses inspired a series of
clinical trials addressing oral mucosal inflammation. We previously reported on the safety and efficacy of fresh,
allogeneic and autologous, adipose-derived mesenchymal stem cells (ASCs) to treat feline gingivostomatitis (FCGS),
an oral mucosal inflammatory disease that shares similarities with human oral lichen planus.
Methods: To meet clinical demand and goals for future commercialization, we determined the feasibility of
shipping fresh ASCs to distant clinics and extended our pilot studies to expand safety and efficacy data for shipped
and non-shipped ASCs in a cohort of 18 FCGS cats enrolled locally and at a few different locations within the USA.
Results: We found that ASCs retained their viability, phenotype, and function after shipment. ASCs administered
systemically resulted in a 72% positive response rate, identical to that noted in our previous studies. Cats that
responded to ASC therapy had a significant decrease in circulating globulin concentration and histological
evidence of decreased CD3+ T cells and CD20+ B cells in the oral mucosa. Responder cats also had significantly
decreased percentages of CD8lo cells in blood prior to and at 3 months post-ASC therapy. CD8lo cells may serve as
a potential “predictor” for response to systemic ASC therapy.
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Conclusion: Fresh feline ASCs can be successfully shipped and administered to cats with FCGS. ASCs modulate the
immune response and demonstrate efficacy for chronic oral mucosal inflammatory lesions that are characterized by
CD8+ T cell inflammation and T cell activation. FCGS is a potentially useful naturally occurring large animal model
of human oral inflammatory diseases.
Keywords: Multicenter, Shipped adipose-derived stem cells, Fresh, Allogeneic, Autologous, Cats, Gingivostomatitis,
Oral mucosa, Immunomodulation
Background
Stem cell therapy is emerging as an approach to treat
patients with chronic inflammatory disorders, and
adipose-derived mesenchymal stem cells (ASCs) are cur-
rently a favored cell type used in clinical trials [1]. ASCs
have a profound regenerative capacity and the ability to
modulate both innate and adaptive immunity resulting
in potent anti-inflammatory effects [1–8]. Although the
mechanism(s) of immunomodulation remain incom-
pletely understood, ASCs can decrease cytokine release
from and suppress proliferation of activated T cells. In
addition, the administration of mesenchymal stem cells
(MSCs) can increase regulatory T cell numbers and
dampen cytotoxic T cell attack on foreign cells or tissues
[9]. MSCs can also alter B cell functions, downregulate
MHC II expression, and inhibit dendritic cell maturation
and differentiation [3, 4, 6, 7, 10]. MSCs inhibit the
mitogen-induced response to naïve T lymphocytes,
CD4+ and CD8+, and natural killer cells [11, 12]. In
addition, MSCs require licensing with interferon gamma
(IFN-γ) to exert their immunosuppressive effects [13].
As such, MSC therapy is being explored for the treat-
ment of immune-mediated diseases.
In cats, in vitro data support the use of ASCs for dis-
eases associated with T cell activation. ASCs inhibit T
cell responses via the secretion of soluble factors and/or
direct cell-to-cell interactions. Feline ASCs decrease acti-
vated T cell proliferation and decrease tumor necrosis
factor alpha (TNF-α) secretion [14]. As with other spe-
cies, IFN-γ is produced by both CD4+ and CD8+ T cells
upon mitogen activation; however, specifically for feline
ASCs, IFN-γ production is enhanced by T cell-ASC con-
tact [14]. This contact is mediated by ASC ICAM-1 (in-
ducible cell adhesion glycoprotein) interacting with the
T cell ligand CD11a/CD18 (β2 integrin) with resultant
inhibition of T cell proliferation via cell cycle arrest in
G0–G1 [14]. These findings deepen our understanding
of how feline ASCs modulate T lymphocyte activity.
Client-owned pets often have naturally occurring dis-
eases that reflect the complexity of human diseases. Data
from these naturally occurring large animal models can
be used to inform best practices for human clinical trials
and can serve as relevant large animal data for investiga-
tional new drug applications [15–17]. Discovery of
therapeutics that works for naturally occurring diseases
in companion animals can drive human clinical trials
[18].
Feline chronic gingivostomatitis (FCGS) is a naturally
occurring immune-mediated oral mucosal disease poten-
tially triggered by a viral etiology such as feline calici-
virus [19–22]. Due to marked similarity in clinical
presentation, histological manifestation, and local and
systemic immune response, FCGS is a candidate for a
large animal model for human conditions such as oral li-
chen planus, stomatitis, pemphigus, and pemphigoid
[22–24]. In both humans and cats, these diseases result
in painful inflammatory mucosal lesions that markedly
affect quality of life and often require long-term im-
munosuppressive therapy. To that end, our group has
reported on the efficacy of autologous and allogeneic
ASCs in the treatment of refractory FCGS in non-
controlled single-center clinical trials [22, 23]. Approxi-
mately two-thirds of FCGS cats treated with two doses
of 20 × 106 intravenously (IV) administered ASCs
responded well to treatment and demonstrated cure or
substantial clinical improvement with no relapse.
Successful single-center clinical trials are insufficient
to demonstrate widespread therapeutic efficacy. They
provide a limited ability to predict the therapeutic utility
of investigational new drugs [25–27]. Successful therap-
ies, identified in single-center clinical trials, can fail to
meet efficacy standards in multicenter clinical trials [25,
26, 28, 29]. For this reason, the Federal Food and Drug
Administration mandates multicenter clinical trials be-
fore drug approval. In this work, we transitioned from a
single- to a multicenter non-randomized clinical trial to
determine the feasibility of ASC therapy for the treat-
ment of refractory FCGS in a larger and more heteroge-
neous patient population.
The first objective of this study was to determine if fe-
line ASCs could be shipped via a commercial courier
and retain their phenotype and potency after 24 or 48 h
of shipment. Our second objective was to increase our
safety and efficacy data in cats treated both locally and
in a small cohort of cats treated at distant locations.
These data serve only as a proof of concept for a larger,
planned multicenter clinical trial. Finally, we enrolled a
small cohort of FCGS cats for up to 6 months prior to
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initiating ASC therapy to serve as their own controls.
These cats served to document that the hematologic, im-
munomodulatory, and clinical improvements we ob-
served after ASC therapy do not occur in the absence of
ASC administration. We hypothesized that (1) feline
ASCs would maintain their viability, phenotype, and po-
tency following shipment; (2) ASC therapy in cats at dis-
tant locations would be safe; and (3) in the absence of
ASC therapy, FCGS would not resolve and associated
hematologic and biochemical abnormalities would not
change. These data will serve as a proof of concept for a
larger, multicenter clinical trial. We enrolled cats at 2
academic and 2 private institutions and found that ASCs
administered systemically within 24 h of shipment re-
sulted in a 72% positive response rate, comparable to
our previous results.
Materials and methods
In vitro shipping study
ASC isolation, expansion, and storage
Feline ASCs from 5 individual donors were thawed and
expanded exactly as previously described [22]. Our ship-
ping study included ASCs derived from cats with FCGS
(n = 3) and ASCs derived from specific pathogen-free
(SPF) cats (n = 2) to determine shipment parameters for
both autologous and allogeneic ASCs. Cats enrolled in
the clinical trial were later administered these same SPF-
derived ASCs. After washing, 20 million ASCs were re-
suspended into 2 mL of lactated Ringer’s solution and
aliquoted into Class B Clear Glass Threaded Vials (Fish-
erbrand™, Thermo Scientific, Ottawa, ON). Vials were
packaged upright and placed into Thermosafe® Insulated
Shippers and a shipment simulation was conducted.
Temperature was monitored using a LogTag® TRIX-8
Recorder packaged within the shipper. Temperature data
was analyzed with LogTag® Analyzer software. Cells were
shipped at 4 °C via FedEx commercial courier.
ASC characterization of phenotype and potency following
shipment
ASC number (cell recovery), viability, sterility, endo-
toxin, cell identity (CD105), purity (CD18), MHC II ex-
pression, and potency (i.e., ability to inhibit activated
lymphocyte proliferation) were determined at time 0
(baseline) and at 24 and 48 h post-shipment. Shipped
ASCs were replated at 5000 cells/cm2 to confirm cell re-
adherence and viability (24 and 48 h). Viable cell number
was determined using the trypan blue exclusion test and
a hematocytometer. Cell viability was confirmed through
7-AAD uptake and analyzed on a flow cytometer
(Cytomics FC500, Beckman Coulter, Miami, FL, USA).
Sterility was determined via aerobic and anaerobic bac-
terial culture (University of California, Davis, Veterinary
Medical Teaching Hospital, microbiology labs), and
Mycoplasma PCR (MycoScope™ PCR Mycoplasma De-
tection Kit, Genlantis, San Diego, CA, USA). Endotoxin
levels were determined (Endosafe® nexgen-PTS™ reading
device, Charles River, Charleston, SC, USA). Surface
protein expression for MHC II (activation), CD105
(identity), and CD18 (purity) were determined using flow
cytometry as described previously [30]. All antibodies
were purchased from the Leukocyte Antigen Biology La-
boratory, University of California, Davis, unless other-
wise indicated. Antibody clones included MHC II (42.3),
CD18 (FE3.9F2), CD105 (SN6; eBioscience, San Diego,
CA, USA), and a mouse IgG-phycoerythrin (PE) anti-
body (Jackson ImmunoResearch Labs, West Grove, PA,
USA) for secondary labeling for unconjugated anti-
bodies. The ability of shipped ASCs to inhibit activated
lymphocyte proliferation was determined using a
leukocyte proliferation assay according to a previously
reported method [22, 23]. ASCs at time 0, 24, and 48 h
post-shipment were co-cultured with allogeneic periph-
eral blood mononuclear cells (PBMCs) stimulated with
ConcanavalinA (ConA, Sigma-Aldrich, St. Louis, MO,
USA), as previously described [22, 31].
In vivo clinical study
Study population
The Institutional Animal Care and Use Committees at
the University of California, Davis, and at Cornell Uni-
versity, and the Clinical Trials Review Board of the Uni-
versity of California, Davis, approved this study. All cat
owners signed an informed consent prior to enrollment.
A total of 18 client-owned cats with refractory FCGS
were recruited to the study between the years 2015 and
2018. Inclusion criteria included cats affected by FCGS
with no other primary co-morbidities that had failed to
respond to full-mouth extractions performed at least 6
months prior to enrollment. All systemic or topical cor-
ticosteroid or other immunosuppressive therapies were
discontinued 2 weeks prior to and for the entire duration
of the clinical trial. The absence of retained tooth root
tips and other underlying lesions were ruled out by full-
mouth radiographs. All cats were confirmed negative for
feline immunodeficiency virus and feline leukemia virus
infection.
Clinical trial design
Cats with FCGS were recruited from four institutions
(University of California Davis, Cornell University, and
two private dental specialty practices) that met the inclu-
sion criteria. Blood was collected for a complete blood
count, serum biochemistry profile, and blood lympho-
cyte phenotyping. The study was non-randomized and
not blinded; however, a cohort of 6 cats was enrolled in
a crossover design where they served as their own con-
trols for 6 months prior to being enrolled in the study.
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Thirteen cats were treated at UC Davis, three cats at
Cornell, and one cat in each of the private specialty
practice (Table 1). Oral mucosal biopsies were collected
prior to ASC administration and at 6 months post ad-
ministration (end of study). Clinical disease severity was
evaluated using a stomatitis disease activity index (SDAI)
scoring system as previously described [22, 23, 32]. The
SDAI scoring was performed at the time of study enroll-
ment and at 6 months after the first ASC administration
(supplemental figure). Briefly, the cats’ owners com-
pleted a questionnaire and scored appetite, activity level,
grooming behavior, and perceived oral comfort on a
scale of 0 to 3. Lesion severity was also scored by a vet-
erinary dental specialist in each participating center and
experienced in FCGS evaluation, as 0 (no lesion), 1
(mild), 2 (moderate), or 3 (severe). The SDAI score for
each cat was calculated at each time point (range = 0, no
disease, to 30, severe disease). Cats were evaluated at day
0 and at 1 month (second injection), 3 months and 6
months after the first ASC treatment (study exit). How-
ever, cats were followed up continually for up to 24
months and data presented include the final recheck as
well. During the study period, the cats received only opi-
oid analgesic management (i.e., buprenorphine or oxy-
morphone) without any immunosuppressive, antibiotic,
or non-steroidal anti-inflammatory medication.
ASC treatment
All cats received two IV transfusions of 20 × 106 (~ 5
million ASCs/kg) fresh (i.e., cryopreserved ASCs that
were revived in culture for ~ 72 h prior to administra-
tion) allogeneic (n = 5) or autologous (n = 13) ASCs,
1 month apart, as previously described [22, 23]. ASCs
are used at passage 2 or 3. Initially, we utilized autolo-
gous ASCs. However, due to the deleterious affect of fe-
line foamy virus on feline ASCs, our work has
exclusively switched to treating FCGS cats with allogen-
eic ASCs [30]. Allogeneic ASCs were derived from 2
separate SPF cats. Cells for treatment were from the
same master cell bank used for the in vitro shipping
study. Cryopreserved ASCs were revived in culture for
~ 72 h prior to administration. Fresh ASCs were pre-
pared and transferred to glass vials. At the University of
California, Davis, the ASCs were used within 2–3 h of
placing the cells in a glass vial. In the other 3 participat-
ing centers (Cornell University and two private specialty
practices), the ASCs were shipped overnight using FedEx
commercial delivery shipment (exactly as described for
the in vitro study) and the cells were administered
within 24 h of placement within the vial. All ASCs were
administered by direct injection over a period of 20–60
min by dividing the total dose into 4 separate aliquots
(~ 5 million cells at a time) to prevent ASC adherence to
syringe plastic and to prevent reactions associated with
rapid cell infusion. All cats were hospitalized for 24 h
post-treatment to monitor for adverse reactions.
Histology and immunohistochemistry
Oral biopsies were fixed en bloc in 10% neutral buffered
formalin, embedded in paraffin, sectioned, mounted, and
Table 1 Demographics of the cats enrolled in the ASC clinical trial including cell source and outcome
Cat # Age (years) Sex Weight (kg) Cell source Treatment site Response SI entry SI exit Last SI Follow-up (months)
1 6 MC 4.3 Autologous UC Davis Cure 19.8 – 0 18
2 5 FS 4.7 Autologous UC Davis No/minimal 19 19 6
3 5 MC 4.5 Autologous UC Davis Substantial 14.75 4 6
4 9 FS 3.3 Autologous UC Davis Substantial 19 12 6
5 7 FS 7 Autologous UC Davis Substantial 12.75 2 12
6 11 MC 5.7 Autologous UC Davis Substantial 23.25 7.5 6
7 3 MC 5 Autologous UC Davis No/minimal 24.75 15.75 6
8 9 MC 4.6 Autologous UC Davis Cure 23.5 0.5 6
9 4.5 FS 3.6 Allogeneic UC Davis Cure 24.5 – 1 12
10 6 MC 11 Allogeneic UC Davis No/minimal 17.12 10 6
11 10 FS 5.6 Autologous UC Davis Substantial 6.25 3.25 18
12 3.5 MC 3.9 Autologous Cornell Cure 12.75 2 24
13 4 MC 4.4 Autologous Cornell Substantial 11.25 11 12.7 13
14 4 FS 6.2 Autologous Cornell Substantial 13.25 11.25 6
15 10 MC 7.3 Allogeneic Oregon Substantial 19 11.75 6
16 11 FS 3.2 Allogeneic UC Davis Cure 24.5 0.5 6
17 4 MC 4.1 Allogeneic UC Davis No/minimal 8.37 6.25 6
18 4 FS 2.9 Autologous San Francisco No/minimal – – 6
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stained with hematoxylin and eosin according to stand-
ard laboratory protocol, as previously described [33, 34].
Immunohistochemistry was performed on 4-mm-thick,
formalin-fixed, paraffin-embedded tissue sections,
mounted on charged slides and air-dried overnight
exactly as previously described [22]. Primary antibodies
and dilutions were rat anti-CD3 (clone 3–12, diluted 1:
10, Leukocyte Antigen Biology Lab, UCD) and rabbit
anti-CD20 (NeoMarker RB-9013-P1; 1:300; Thermo
Fisher Scientific, Pittsburgh, PA, USA). A board-certified
veterinary pathologist experienced in oral pathology and
regenerative medicine (NV) interpreted all biopsies.
Bloodwork and lymphocyte phenotyping
Blood samples were collected into EDTA Vacutainers (BD
Biosciences, San Jose, CA, USA) for a complete blood cell
count (CBC) using an automated analyzer (Bayer ADVIA
120; Bayer Diagnostics, Tarrytown, NY, USA). Serum was
isolated from whole blood collected without an anticoagu-
lant, centrifuged (1000g for 10min) and submitted for a
full biochemical profile (Cobas c501; Roche Diagnostics
International, Risch, Switzerland, http://www.roche-diag-
nostics.ch). Lymphocytes were phenotyped (CD4, CD8,
CD21) exactly as previously described [22, 23].
Ex vivo mixed leukocyte reaction
Lymphocyte proliferative ability, in response to mitogen
activation ex vivo, was determined in FCGS cats prior to
and at 6 months post-ASC administration. In brief, fe-
line PBMCs were isolated from whole blood using gradi-
ent centrifugation and activated with 5 mg/mL ConA.
Cells were incubated for 4 days. The degree of lympho-
cyte proliferation was determined through 5-bromo-2′-
deoxyuridine (BrdU) incorporation. Wells were spiked
with BrdU at day 3 and then cells were collected and
processed per the manufacturer’s instructions (BrdU
Flow Kit; BD Biosciences) at day 4 [22, 23].
Statistical analyses
All data were assessed for their distribution by the
D’Agostino-Pearson normality test. A Grubb’s test was
used to determine if there were outliers (no outliers
were detected or excluded). Parametric tests were per-
formed only on data with Gaussian distribution. The dif-
ference within groups at different time points was
determined either with repeated-measure or one-way
ANOVA or Kruskal-Wallis test. The difference between
2 groups at specific time points was determined using
Student’s t test or Mann-Whitney test. A two-tailed
nonparametric Wilcoxon matched-pairs test was used
for MSC potency. In all cases, p values < 0.05 were con-
sidered statistically significant. Statistical analysis was
performed using GraphPad Prism Version 5.02 software
(Graphpad Software, San Diego, CA, USA).
Results
ASCs successfully maintained viability, function, and
phenotype after shipment
All 5 ASC cultures were successfully maintained at 4 °C
throughout the shipping period (24 and 48 h). The total
cell number decreased after 24 h (average 20% decrease)
and after 48 h of shipment (average 24% decrease com-
pared to baseline) although the changes were not signifi-
cant (Fig. 1a). There was no reduction in cell viability over
time (Fig. 1b) and all cells readily re-adhered, proliferated,
and maintained normal cell morphology after re-plating.
All cells at all time points were Mycoplasma-negative and
had endotoxin levels < 5 EU/mL (safe for clinical injec-
tion). All cells were bacterial culture-negative at time 0
and at 24 h; however, at 48 h, 2 of the 5 cells were culture
positive with low-level plate contaminants with non-
enteric species. MHCII (MSC activation) and CD18 (MSC
purity) expression was < 1% on all cells at all time points
(Fig. 1c). The expression of CD105 (MSC identity) did not
significantly change over time (CD105 decreased an aver-
age of 12%), remaining > 85% positive over time (Fig. 1c).
All 5 ASC cultures significantly inhibited activated
lymphocyte proliferation at time 0 (p = .03), 24 (p = .03)
and 48 h (p = .04) after shipment (Fig. 1d). Given the occa-
sional positive bacterial culture at 48 h, ASCs were admin-
istered within 24 h after placement in the vial for the
multicenter clinical trial.
Autologous and allogeneic ASCs therapy induced marked
clinical improvement in cats with FCGS in shipped and
non-shipped cells
Of the 18 cats that were enrolled (10 males, 8 females),
17 completed the study to 6 months (Table 1). One cat
was lost to follow up after the 3months recheck, and
that cat had substantial improvement at 3 months. Of
the 13 cats that received autologous cells, 77% (10/13)
were categorized as having substantial improvement or
cure determined by oral examination, photographs, hist-
ology, and stomatitis index. Of the 5 cats that received
allogeneic cells, 60% (3/5) were categorized as having
substantial improvement or cure. Breaking this down
further, 5/18 cats (27.8%) responded to treatment with
complete cure (Fig. 2a) and 8/18 cats (44.4%) exhibited
substantial clinical improvement. Taken together, 72.2%
of the cats in this study exhibited a positive clinical re-
sponse to ASC treatment. The cats with substantial im-
provement/cure were enrolled at the University of
California, Davis; Cornell University; and a private prac-
tice in Oregon. It is important to note that, as reported
previously [22, 23], clinical response was observed be-
tween 3 and 6months after ASC administration. Finally,
5/18 (27.8%) cats did not respond to treatment or had
minimal improvement.
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The SDAI was completed on all but one patient. Clin-
ical assessment of disease severity, by means of the
SDAI, was generally in agreement with our clinical ob-
servations (Fig. 2b, c). In general, the improvement of
clinical signs corresponded with the improvement of the
oral mucosal lesions. Responder cats gained weight and
returned to normal eating behavior, grooming, and soci-
ability. Cat owners reported a return to pre-FCGS activ-
ity levels in the responder cats. The 5 cats that did not
respond to treatment had static or worse SDAI.
Oral inflammation, hematologic values, and biochemical
parameters did not improve over 6months in the
absence of ASC therapy
One of the goals of this study was to enroll a small cohort
of FCGS cats as controls to determine if (1) cats would cure
in the absence of ASC therapy and (2) the hematologic al-
terations that we had previously noted (i.e., CD8lo cells,
globulin concentration, and neutrophil number) would
change in the absence of ASC therapy. We enrolled 8
FCGS cats as their own controls prior to crossing them
over into the treatment group. Six of these cats (75%) were
maintained for the full 6months prior to ASC therapy; 2 of
these cats were maintained for only 3months prior to
crossing them over into the treatment group due to severe
progressive disease. None of the 8 cats experienced sub-
stantial disease improvement or cure in the absence of ASC
therapy. There were no significant differences in percent
CD8+ T cells, CD4/CD8 ratio, percent CD8lo cells, or
globulin concentration in the 6months prior to ASC ad-
ministration in these control FCGS cats (Fig. 3a-d).
Cats that respond to ASC therapy have decreased
globulin concentration over time and a lower percentage
of circulating CD8lo T cells prior to therapy
Thirteen cats received autologous ASCs and 5 cats received
allogeneic ASCs. No significant differences were detected in
hematologic or biochemical data between FCGS cats that
received allogeneic ASCs and FCGS cats that received au-
tologous ASCs. As such, their data were combined for all
Fig. 1 ASC characterization prior to and after shipping. a Normalized ASC cell counts for all three time points—0 h, 24 h, and 48 h. b Percent
viability of ASCs at 4 °C for all 3 time points. c ASC surface phenotype. d Normalized suppression of lymphocyte proliferation for all three time
points. N = 5 for all experiments. The % of proliferating lymphocytes was normalized to PBMC stimulated with ConA. Abbreviations: BrdU, 5-
bromo-29-deoxyuridine; ConA, concanavalin A; PBMC, peripheral blood mononuclear cell
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bloodwork analyses (p > 0.05). Cats with FCGS had a vari-
able leukocytosis due to a neutrophilia, as well as hyperglo-
bulinemia. Responder and non-responder cats mostly did
not differ in basic white blood cell parameters, total protein
concentration, or albumin concentration over time (data
summarized in Table 2). Responder cats had a significantly
higher neutrophil count at 3months (p = 0.05, Table 2)
than non-responders. However, this difference was not
noted by the end of the study. Cats that responded to ASC
therapy had a significantly decreased total protein concen-
tration at 3months due to decreased globulin concentra-
tion (p = 0.05, Table 2, Fig. 3d), and the significant decrease
in globulin concentration was sustained at 6months (p =
0.01). The majority of cats (8/14, 57%) had increased
percentages of CD8+ T cells in blood prior to treatment
(day 0, Fig. 3a). The percentage of circulating CD8+ T cells
tended to increase over time in the non-responders, sug-
gesting sustained cytotoxic immune activation. However,
cats that responded to ASC therapy demonstrated decreas-
ing percentages of CD8+ T cells, but the difference was not
statistically significant (Fig. 3a). The CD4/CD8 ratio did not
significantly change prior to or after ASC therapy regardless
of response to ASC therapy (Fig. 3b). Previously, we re-
ported on decreased percentages of CD8lo T cells (at time
0) as being one potential biomarker that predicted response
to ASC therapy in cats with FCGS. This finding was reca-
pitulated for cats in this study. Compared with cats that did
not respond, cats that responded to ASC therapy had
Fig. 2 Clinical assessments of disease severity by means of clinical images and stomatitis disease activity index (SDAI) over time. Representative
pre-treatment images for 2 different cats (A1, B1) are characterized by severe proliferative and ulcerative inflammation of the caudal oral cavity,
the area lateral to the palatoglossal folds. Note the profound improvement with complete cure in one cat (A2) and a substantial improvement in
the other (B2). In the cat depicted in B1 and B2, there was also glossitis that improved substantially. SDAI graph demonstrating the score at entry
and exit examination (see Table 1) as well as the last recheck available. Non-responder cats are color-coded (blue = cat#7, yellow = cat#3, red =
cat#10, green = cat#17). Abbreviation: SI, stomatitis index
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significantly lower percentages of CD8lo T cells at day 0
(p = 0.02, Fig. 3c) and at 3months post-treatment (p = 0.05,
Fig. 3c). Like all other parameters, the percentage of CD8lo
cells did not change in the 3–6months prior to ASC ther-
apy (Fig. 3d).
ASC therapy results in decreased lymphocyte proliferative
ability in the majority of responder cats
The ability of lymphocytes from FCGS patients to prolif-
erate in response to mitogen activation was tested prior
to and at 6 months post-ASC administration. At base-
line, lymphocyte proliferation in FCGS cats was compar-
able to healthy control cats (Fig. 4). At 6 months post-
ASC therapy, 75% of the cats that responded to therapy
had decreased lymphocyte proliferative ability compared
to their baseline. On the contrary, 80% of the cats that
did not respond to therapy at 6 months demonstrated
comparable or greater proliferative capability as com-
pared to their baseline. Due to marked individual vari-
ation in absolute lymphocyte proliferative response, the
Fig. 3 Bloodwork and PBMC proliferative response in FCGS patients receiving ASC treatment. Changes in a percentage of CD8+ T cells and b
CD4+/CD8+ T cell ratio; c percentage of CD8+ T cell with CD8 receptor downregulation (CD8lo cells) out of total CD8+ T cells; and d serum
globulin level, measured prior to and after ASC administration. Note the significant reduction in serum globulins in responder cats corresponded
to clinical improvement. Reduction in CD8lo cells was also significant between pre- and post-ASC therapy. Representative flow cytometry plots for
CD8+ and CD8lo populations for e non-responder FCGS-affected cat at day 0; f responder FCGS-affected cat at day 0; and g responder FCGS-
affected cat at 6-month follow-up after ASC treatment. CD8lo percentages of CD8+ cells based on flow cytometry gates shown in e–f for all cats
in the study. Non-responder cats had a significantly higher percentage of CD8lo cells before ASC treatment (Mann-Whitney test; p = 0.02)
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data between responders and non-responders were not
statistically different (Fig. 4).
Histopathologic features correlated with clinical findings
in cats receiving shipped and non-shipped ASCs
Oral mucosal biopsies were obtained from all cats prior
to study enrollment and at 6 months post-ASC treat-
ment. The histopathological features of the present study
were identical to our previous reports [22, 23, 33]. In all
pretreatment biopsies, the epithelium and sub-epithelial
stroma were expanded by a mixed inflammatory infil-
trate composed of lymphocytes, plasma cells, and neu-
trophils, with occasional Mott cells, mast cells, and
histiocytes. Ulceration of the surface epithelium was fre-
quently observed. Remnant surface epithelium was hy-
perplastic with multiple rete pegs extending deep into
the subjacent stroma. Immunohistochemistry revealed
that CD3+ T cells were present within the epithelium
and sub-epithelial stroma, while CD20+ B cells were re-
stricted to the sub-epithelial stroma. The biopsies ob-
tained from the non-responder cats at 6 months post-
treatment were similar to the pre-enrollment biopsies.
In the cats that demonstrated substantial clinical im-
provement, a profound reduction of inflammation was
observed histologically: occasional lymphocytes were ob-
served within the sub-epithelial stroma, with no evidence
of epithelial hyperplasia, ulceration, or inflammation. In
cats that exhibited cure, a complete return to normal tis-
sue architecture with no inflammatory cell infiltrates was
observed (data not shown).
Adverse effects
Four cats (1 at the University of California, Davis; 2 at
Cornell University; and 1 at a private practice) developed
edema in the forelimb that was used for IV ASC admin-
istration. For two cats, the IV catheter was removed, di-
phenhydramine was administered, and the edema
resolved within several hours with no further conse-
quences. One cat developed skin necrosis, experienced
prolonged skin recovery, and underwent skin grafting.
The cat is now doing well. For the 2 cats that developed
edema of the forelimb at the first ASC administration, a
Table 2 Selected hematologic and biochemical parameters of FCGS patients prior to and after ASC therapy
Parameters Non-responders (n = 5) Responders (n = 13) p
valueTime point Mean SD Range Mean SD Range
White blood cell count (/μl) Pre-treatment 10,948 1659 8740–12,340 13,807 7410 3900–28,080 0.53
3 months 8980 4158 5530–13,597 12,284 5966 6200–28,300 0.05*
6 months 13,667 1527 11,230–15,270 13,652 6713 6700–29,400 0.90
Lymphocyte count (/μl) Pre-treatment 2597 643.9 1713–3122 1969 970.5 741–3973 0.23
3 months 2082 634.8 1466–2734 1986 1161 926–5452 0.19
6 months 2870 1018 1771–3780 2308 1676 986–6582 0.18
Neutrophil count (/μl) Pre-treatment 7254 1223 6092–8724 10,422 6878 2145–22,717 0.61
3 months 5326 4070 2544–9998 8831 5923 2820–24,338 0.08
6 months 9598 2724 7705–12,720 10,398 6859 3021–26,372 0.75
Total protein (g/dl) Pre-treatment 9.45 0.6856 8.5–10 8.462 0.76 7.3–9.5 0.10
3 months 9.6 1.127 8.3–10.3 8.6 0.6015 7.6–9.4 0.05*
6 months 9.233 0.7572 8.7–10.1 8.36 0.6931 7.5–9.4 0.16
Albumin (g/dl) Pre-treatment 2.925 0.1708 2.7–3.1 3.108 0.5664 2.3–4.1 0.71
3 months 2.667 0.3215 2.3–2.9 2.867 0.3339 2.4–3.6 0.99
6 months 2.5 0.2646 2.2–2.7 3 0.3742 2.4–3.7 0.27
Fig. 4 The proliferative response of PBMCs from FCGS patients prior
to and after treatment with ASCs as determined through BrdU
incorporation. Sample sizes (n), 3–6 cats for non-responder group
and 11–13 cats for responder group; pre, prior to ASC treatment,
post, after ASC treatment, D0, day 0; 3M, 3-month follow-up; 6M,
6-month follow-up
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central line was placed for the second dose. Two of the
above cats also experienced an increase in respiratory
rate during treatment that lasted several hours and also
resolved spontaneously, and two additional cats experi-
enced vomiting and diarrhea immediately after the treat-
ment, which resolved spontaneously within a few hours.
Apart from these non-life-threatening complications, no
other side effects were noted.
Discussion
In this study, we report our first multicenter experience
using shipped and non-shipped ASCs for the treatment
of a chronic, naturally occurring oral mucosal disease in
a large animal model. First, we found that ASCs success-
fully maintained viability, function, and phenotype dur-
ing shipment with a commercial courier at 4 °C for at
least 48 h. Importantly, regardless of the cell source
(allogeneic or autologous), ASC therapy induced marked
clinical improvement in cats with FCGS even after ship-
ment. Similar to our previous work, cats with a de-
creased percentage of CD8lo T cells were more likely to
respond to ASC therapy [22]. Finally, cats that
responded to therapy had a substantial reduction in oral
mucosal inflammation and in systemic inflammation, as
evidenced by decreased globulin concentration. The ma-
jority of responder cats also had decreased lymphocyte
proliferative ability ex vivo at the end of the study com-
pared to day 0. The systemic administration of ASCs
was generally safe, although some adverse events were
noted in 6 cats.
MSCs are currently one of the most used cells in pre-
clinical and clinical trials in humans and animals [35,
36]. However, there is substantial variability in clinical
outcomes that limit MSC use and regulatory approval.
Discrepancies in clinical outcomes have been attributed
to cell culture, expansion and storage protocols, and cell
source as well as the method of transportation [37, 38].
Specifically, MSC viability and function may be altered
in the time between processing at the laboratory and ad-
ministration to the patient. Hence, cell transport re-
quires precise evaluation and control of the temperature
and shipping conditions to optimize safety and efficacy
[39]. In the first part of the study, we found that fresh
ASCs successfully maintained viability, function, and
phenotype after shipment with a commercial courier at
4 °C for up to 48 h. These data agree with previous stud-
ies of human bone marrow-derived MSC storage that
demonstrated satisfactory viability for 24 h at 4 °C [40,
41]. Our data suggest that shipment in lactated Ringer’s
for up to 48 h would be acceptable other than the low
level of bacterial contamination noted. ASC lines cul-
tured in clinical laboratories, even under good manufac-
turing practices or good laboratory practice protocols,
can have low-level bacterial growth using standard
microbiology techniques (usually a contaminant). This is
not an issue limited to MSC culture but rather is a long-
standing issue in all cell therapy fields [42]. Regardless,
our current recommendation for feline ASC lines that
are processed and shipped from our clinical laboratory is
that the cells be administered within 24 h of processing.
Chronic inflammatory oral mucosal diseases such as
FCGS and oral lichen planus and stomatitis in humans
are thought to have a complex and heterogeneous
pathogenesis. It is believed that FCGS is triggered by or
associated with feline calicivirus, but the exact etiology
remains elusive [19, 20]. Regardless, FCGS and oral li-
chen planus have several commonalities: both are
chronic inflammatory diseases affecting the oral mucous
membranes, both are T cell-mediated diseases in which
CD8+ cytotoxic T cells predominate in affected tissues,
and T cells (mostly CD8+ and some CD4+ cells) migrate
from the systemic circulation to the mucosal epithelium.
Both diseases are also associated with elevated serum
levels of globulins, primarily IgGs [33, 43–45].. Our data
suggest that IV administration of fresh ASCs can modu-
late these features of immune-mediated disease. Disease
improvement or resolution of clinical signs was associ-
ated with a decreasing percentage of circulating CD8+ T
cells and a significant reduction in globulin concentra-
tion. Finally, in the ex vivo mixed lymphocyte reaction,
lymphocytes from the majority of cats that responded to
ASC therapy were less proliferative to mitogen at 6
months (compared to their own baseline), whereas lym-
phocytes from the majority of cats that did not respond
to ASC therapy were as or more responsive to ex vivo
stimulation at 6 months. Together, these data support
potent immunomodulatory effects post-MSC adminis-
tration [46, 47].
We previously reported on the presence of decreased
percentages of CD8lo T cells as being one potential bio-
marker for predicting a response to ASC therapy in cats
with FCGS. Similarly, cats in this study that responded
to ASCs had significantly lower CD8lo T cells than cats
that did not respond to therapy. Although some cats in-
creased the number of CD8lo cells in association with
disease improvement, there was no real trend in CD8lo
cells changing with therapy in responder or non-
responder cats. CD8lo cells are associated with viral in-
fections in cats, humans, and mice [48–50]. CD8lo cells
may represent a subset of activated CD8 effector/sup-
pressor cells capable of downregulating the activation of
naïve T cells. A decreased percentage of CD8lo cells may
imply that responder cats have decreased suppressor
function (or less tolerogenic CD8 T cell subsets).
Regardless of the cell source (autologous or allogen-
eic), ASCs administered systemically induced marked
clinical improvement in cats with FCGS achieving
complete resolution or a substantial reduction in oral
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mucosal inflammation in 72.2% of the cats. These find-
ings are similar to our previous reports on smaller co-
horts of cats [22, 23]. Clinical response to therapy
generally took 3–6months, as has been observed in our
previous studies, and clinical response/cure has been
permanent [22, 23]. While we cannot assert the reason
for the delayed response, it is plausible that ASCs are
acting through systemic mechanisms that induce im-
mune cell senescence, prevent the activation of new T
cells, or provide regulatory signals to downregulate cells.
In these scenarios, a clinical response would only be vis-
ible after a substantial number of pathogenic cells be-
came exhausted or underwent apoptosis [51–53]. This is
clinically relevant as it can be difficult to assure protocol
compliance (client and clinician) when the response to
therapy is delayed.
For this study, we enrolled 8 cats to serve as their own
controls prior to cell administration (crossover design)
to determine if the clinical response and hematologic pa-
rameters, especially CD8 and CD8lo cell counts, would
change in the absence of therapy. In our control cats, we
found no evidence of improvement in clinical disease or
alterations in hematologic data in the absence of ther-
apy. These data are compatible with the fact that spon-
taneous recovery from refractory FCGS has never been
reported [54].
Adverse reactions, related to swelling and edema of the
leg that was used for systemic administration of ASCs,
were noted in 4 cats. IV ASC administration to cats with
FCGS results in immediate adherence of some ASCs to
the vein close to the site of administration, with the ma-
jority of cells retained in the lungs, and a small proportion
of ASCs trafficking to the inflamed oral mucosa [23].
Swelling and edema could be related to microscopic cell
clumping. ASCs are large, and cell size and diameter are
major determinants of vascular obstruction and complica-
tions emerging from it, such as the limb edema noted here
[55, 56]. Furthermore, IV transplantation may cause
microembolism [57]. Local microembolism can cause ag-
gravated mechanical vascular obstruction and resultant
edema and swelling. In addition, the cephalic vein that
was used for administering ASCs in cats is fairly small and
using a larger vein such as the jugular (i.e., a central line)
may be a safer option. In 3 cats, once the catheter was re-
moved and the cat was motivated to change position, the
edema resolved within a few hours. The serious complica-
tions of leg edema and resultant skin necrosis seen in one
cat suggest that mild swelling and/or edema should be
promptly evaluated and addressed.
Conclusion
In summary, we show that feline ASCs successfully
maintain their viability, function, and phenotype during
shipping with a commercial courier. Furthermore, we
demonstrate that in a larger cohort of cats and in a small
multicenter setting, feline ASCs administered systemic-
ally resulted in favorable clinical, histologic, and systemic
response in over 70% of cats. Substantial resolution or
cure of FCGS also resulted in a significant reduction in
serum globulins and, for most cats, a decreased ex vivo
lymphocyte proliferative response. Decreased CD8lo cells
may serve as a potential “predictor-biomarker” for the
likelihood of response to systemic ASC therapy. Harnes-
sing FCGS as a potentially useful naturally occurring
large animal model, we demonstrate the clinical poten-
tial of ASC’s immunomodulatory function for therapy of
chronic oral mucosal inflammatory lesions that are char-
acterized by CD8+ T cell inflammation and T cell activa-
tion. The encouraging results of this study are
potentially translatable for the treatment of human oral
inflammatory diseases.
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